Degarelix
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Degarelix: From Prostate Cancer to Hypertrichosis
One-Sentence Summary
Degarelix is a GnRH (gonadotropin-releasing hormone) receptor antagonist established in oncology for advanced hormone-dependent prostate cancer, though it holds no current UK marketing authorisation and its formal mechanism-of-action record in this evidence pack remains a data gap. The TxGNN model’s top-ranked prediction for this drug is Hypertrichosis (disease), with a very high similarity score (99.99%) but zero supporting clinical trials and zero literature. This is a model-only prediction (Evidence Level L5) with a weak, non-specific mechanistic rationale, and the recommended decision is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Advanced hormone-dependent prostate cancer (from published prescribing information; not confirmed within this evidence pack — see Data Gaps below) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Degarelix is flagged as a data gap in this evidence pack (DG002, High severity). Based on information embedded elsewhere in the pack’s own repurposing rationale, Degarelix acts as a GnRH receptor antagonist: it directly blocks pituitary GnRH receptors, suppressing LH/FSH release and, downstream, testosterone production. This androgen-deprivation mechanism underlies its established oncology use.
The proposed link to hypertrichosis (excessive hair growth) rests on the idea that if a case of hypertrichosis is androgen-driven (i.e. related to hyperandrogenism), suppressing testosterone could plausibly reduce it. However, the evidence pack’s own rationale is explicit that this connection is weak: the general hypertrichosis category is most commonly caused by drug exposure, congenital factors, or other non-hormonal mechanisms unrelated to androgen signalling. The mechanistic link is therefore described as “unclear and overly generic” rather than disease-specific.
In short, while the TxGNN similarity score is very high, no biological specificity or independent evidence currently substantiates this particular pairing — the score alone should not be read as clinical plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Degarelix does not currently hold a UK marketing authorisation (0 licences recorded in this evidence pack), so no MHRA product entry is available to summarise.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Hormonal/endocrine antineoplastic (GnRH receptor antagonist; androgen-deprivation therapy) — not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Not established in this evidence pack; GnRH antagonists are not typically associated with significant myelosuppression |
| Emetogenicity Classification | Not established in this evidence pack |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: this evidence pack flags TFDA/SmPC warnings and contraindications as a Blocking data gap (DG001) — a formal safety review cannot proceed to S1 until this is resolved.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction is supported only by a TxGNN similarity score, with no clinical trials, literature, mechanistic specificity, or UK regulatory footing (drug not marketed) to corroborate it.
To proceed, the following is needed:
- Resolution of the Blocking safety data gap (DG001: SmPC warnings/contraindications)
- Confirmation of mechanism of action and original licensed indication (DG002)
- Any preclinical or case-level evidence specifically linking GnRH antagonism to androgen-driven hypertrichosis
- Re-evaluation should Degarelix obtain UK marketing authorisation
Note: within this same evidence pack, rank 9 (“central precocious puberty 1”) shows a substantially stronger and more disease-specific mechanistic rationale — Degarelix’s GnRH-antagonist action directly parallels the established use of GnRH agonists in this condition — and is scored “Research Question” rather than “Hold”. It may warrant separate evaluation despite its lower TxGNN rank.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.